A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

NCT02858440 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

Diphtheria
Tetanus
Pertussis
Hepatitis B
Haemophilus Influenzae Type b

Interventions

BIOLOGICAL: Infanrix-IPV/Hib

Sponsor

GlaxoSmithKline